How to protect patients and payment with same-day re-draw/re-dose loops

Polypharmacy is the use of five or more medications by an individual, which increases the risk of adverse drug events, drug-drug interactions, and harm. It is particularly common in older adults with multiple chronic conditions and can be caused by factors like multimorbidity, multiple prescribers, and system-level issues like poor medication records. Managing polypharmacy involves strategies like creating a complete medication list, reviewing and deprescribing unnecessary drugs, and educating patients on potential risks.

FDA issues draft guidance to accelerate nonopioid chronic pain treatments The new guidance focuses on: ✅ Efficient trial design and patient selection ✅ Meaningful endpoints and patient-reported outcomes ✅ Mechanistic evaluation of drugs and chronic pain conditions This effort aims to reduce reliance on opioids and support safer, effective therapies for millions living with chronic pain. Stakeholders can submit feedback for 60 days. Full details: https://lnkd.in/e3avGdAE #ChronicPain #PainManagement #NonOpioid #FDAGuidance #PatientCare #ClinicalTrials #PublicHealth

💊🌎 The FDA is pushing for a future with safer, non-opioid treatments for chronic pain. Its latest draft guidance offers clarity on trial design, evidence standards, and expedited pathways—giving developers the tools to bring lower-risk therapies to patients faster. Get the full breakdown here ➡️ https://ow.ly/oWgg50WXP3L

Understanding the Naranjo Adverse Drug Reaction Probability Scale Ever wondered if a patient's symptoms are actually caused by their medication? The Naranjo Scale (developed in 1981) is a simple tool that helps answer this question. What Is It? The Naranjo ADR Probability Scale is a 10-question assessment that determines whether a drug likely caused an adverse reaction. It was originally designed for clinical trials but is now widely used in practice to standardise causality assessment. How does it work? Healthcare providers answer 10 straightforward questions with "Yes," "No," or "Do Not Know," such as: Did the reaction appear after the drug was given? Did it improve when the drug was discontinued? Did it reappear upon rechallenge? Are there alternative causes? Was there a dose-response relationship? Each answer gets a point value (-1 to +2), and the total score (ranging from -4 to +13) determines the likelihood: ≥9 points: Definite ADR 5-8 points: Probable ADR 1-4 points: Possible ADR ≤0 points: Doubtful ADR

Adverse Drug Events are a $30–100 Billion Dollar Problem We Can Actually Solve. Every year in the U.S.: • 1 in 5 patients takes 5+ medications — often with little personalized oversight • Up to 50% experience a clinically significant drug–drug or drug–gene interaction • 1.3 million ED visits are caused by ADEs annually • ADE-related costs exceed $30–100 billion per year What’s worse? Most of these events are preventable with better medication management, pharmacogenomic (PGx) testing, and smarter follow-up. At MedMind, we’re helping health plans and providers identify risks early, personalize therapy, and prevent avoidable hospitalizations, starting with PGx-guided polypharmacy reviews for complex patients. Partner with us to reduce ADEs and improve outcomes.

Statins are widely prescribed, but are we missing their hidden risks? Dr. Shallenberger shows evidence that these drugs might decrease heart muscle strength and vascular function, potentially contributing to the rise in congestive heart failure.  It’s essential for healthcare professionals to question the long-term effects of statin use.  Follow for more insightful discussion for a better understanding of this common prescription. #DrShallenberger #statins #hearthealth #cholesterol #cardiovascularhealth #congestiveheartfailure #healthawareness #heartdisease #healtheducation

𝐓𝐡𝐚𝐭 𝐦𝐨𝐦𝐞𝐧𝐭 𝐲𝐨𝐮 𝐬𝐩𝐨𝐭 𝐚 𝐝𝐚𝐧𝐠𝐞𝐫𝐨𝐮𝐬 𝐝𝐫𝐮𝐠 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐨𝐧 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐭 𝐡𝐚𝐫𝐦𝐬 𝐚 𝐩𝐚𝐭𝐢𝐞𝐧𝐭—𝐭𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐩𝐢𝐧𝐧𝐚𝐜𝐥𝐞 𝐨𝐟 𝐨𝐮𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐯𝐚𝐥𝐮𝐞. As pharmacists, we are the shield against these hidden risks. But not all interactions are obvious. Here’s my mental checklist for the major mechanisms: ⚗️ 𝐀𝐛𝐬𝐨𝐫𝐩𝐭𝐢𝐨𝐧:  Think PPIs & azoles, or iron & levothyroxine. 🧬 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐬𝐦: Know your CYP inhibitors (↑ levels) and inducers (↓ levels). 💧𝐄𝐱𝐜𝐫𝐞𝐭𝐢𝐨𝐧: e.g., NSAIDs + lithium = trouble. 🤝🏾𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐝𝐲𝐧𝐚𝐦𝐢𝐜𝐬: Anticoagulants + NSAIDs = bleeding risk. 𝐀𝐥𝐰𝐚𝐲𝐬 𝐅𝐥𝐚𝐠 𝐓𝐡𝐞𝐬𝐞 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐏𝐚𝐢𝐫𝐬: •Warfarin + Azoles/Macrolides •Simvastatin + strong CYP3A4 Inhibitors •Digoxin + Amiodarone/Verapamil •Lithium + ACEIs/NSAIDs/Diuretics This mechanistic understanding lets us predict, prevent, and protect. It's why our role is non-negotiable for patient safety. 𝙒𝙝𝙖𝙩'𝙨 𝙩𝙝𝙚 𝙢𝙤𝙨𝙩 𝙘𝙤𝙢𝙥𝙡𝙚𝙭 𝙤𝙧 𝙨𝙪𝙧𝙥𝙧𝙞𝙨𝙞𝙣𝙜 𝙙𝙧𝙪𝙜 𝙞𝙣𝙩𝙚𝙧𝙖𝙘𝙩𝙞𝙤𝙣 𝙮𝙤𝙪'𝙫𝙚 𝙧𝙚𝙘𝙚𝙣𝙩𝙡𝙮 𝙢𝙖𝙣𝙖𝙜𝙚𝙙? 𝙎𝙝𝙖𝙧𝙚 𝙮𝙤𝙪𝙧 𝙨𝙩𝙤𝙧𝙮 𝙗𝙚𝙡𝙤𝙬👇🏿 #Pharmacist #DrugInteractions #ClinicalPearls #PatientSafety #MedSafety #Healthcare

What does "value" really mean to patients and families? Melody Joy Paine shares a powerful story from a Rett syndrome family that reminds us why patient-centered outcomes matter. Not every life-changing moment shows up in a questionnaire. Watch this clip, then catch the full conversation to hear how leaders are rethinking trial endpoints to reflect what matters most to patients. Watch the full webinar: https://shorturl.at/cO56a #PatientCentricity #ClinicalTrials #RareDisease #OutcomesThatMatter #HealthEquity #Pharma

Did you know bevacizumab and trastuzumab biosimilars have captured 80% market share in 2023?   And there's more...   Each additional biosimilar competitor leads to a 10-13% price reduction, while maintaining rigorous safety and efficacy standards. Medicare alone has saved $10-15 billion from these two biosimilars between 2019-2023.   These trends are reshaping patient access to treatment.   Download the complete infographic: link in the comments 💡 #SyenzaInsights #Biosimilars #HealthcarePolicy #MarketAccess

Dear doctors, Clinical data is trusted more than anything in your practise... So why don’t we make DEXA scans (or equivalent muscle–fat composition tools) part of the mandatory process before prescribing GLP-1s? Because here’s the risk no one talks about: • GLP-1s help with fat loss ✔️ • But they also cause lean muscle loss ❌, especially if diet and exercise aren’t optimized. Without muscle protection, patients risk weaker metabolism and higher long-term dependency. It’s not one vs. the other. It’s both together, and data-backed tools like DEXA can help us bridge the gap. Would you support making DEXA scans a standard checkpoint before GLP-1 therapy? Shouldn’t it be included as a SOP and part of the process for prescribing GLP-1 drugs ?